Ubroqvu (ubrogepant) is considered an expensive medication. While specific pricing can fluctuate based on insurance coverage, pharmacy, and dosage, the wholesale acquisition cost for Ubroqvu can be several hundred dollars per dose [1].
What factors influence Ubroqvu pricing?
The list price of Ubroqvu is a starting point, and the actual cost to a patient can vary significantly due to several factors. These include:
* Insurance Coverage: Prescription drug benefits offered by insurance plans play a crucial role. Plans may have different co-pays, deductibles, and co-insurance amounts for Ubroqvu. Some plans might also have prior authorization requirements [2].
* Manufacturer Discount Programs: AbbVie, the manufacturer of Ubroqvu, offers savings programs for eligible commercially insured patients. These programs can reduce out-of-pocket costs, potentially bringing the monthly cost down to a fixed amount for certain patients [3].
* Pharmacy and Location: Prices can differ between retail pharmacies and mail-order services, and may also vary by geographic location.
* Dosage and Quantity: The prescribed dosage and the number of tablets dispensed will directly impact the overall cost. Ubroqvu is available in 25 mg and 50 mg tablets [4].
How does Ubroqvu's cost compare to other migraine treatments?
Ubroqvu belongs to a class of drugs known as CGRP receptor antagonists, which generally represent a newer and often more expensive category of migraine treatments compared to older, more established medications like triptans [5]. While these newer agents offer a different mechanism of action and may be effective for patients who haven't responded to other treatments, their higher price point can be a barrier.
Can I get financial assistance for Ubroqvy?
For commercially insured patients who meet eligibility criteria, AbbVie offers the Ubroqvu Savings Card program. This program can help reduce out-of-pocket expenses. Additionally, patient assistance programs from charitable organizations may be available for uninsured or underinsured individuals, though eligibility requirements apply [3].
When did Ubroqvu receive FDA approval?
The U.S. Food and Drug Administration (FDA) approved Ubroqvu on December 23, 2019, for the acute treatment of migraine with or without aura in adults [6].
Sources:
[1] https://www.drugpatentwatch.com/drug/ubroqvu
[2] https://www.ubrovqvu.com/migraine-treatment-cost-and-savings
[3] https://www.ubrovqvu.com/migraine-treatment-cost-and-savings
[4] https://www.ubrovqvu.com/how-ubroqvu-works
[5] https://www.drugpatentwatch.com/blog/understanding-migraine-treatment-costs-and-insurance-coverage
[6] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-continuances-december-2019